Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries
Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2164-2173
DOI: 10.1016/j.ard.2026.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Louise Majormoen Nielung und 12 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases and the DANBIO Registry, Center for Rheumatology and …. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antirheumatic Agents, Biological Products. Die Arbeit nennt 47 Literaturangaben. Gefördert von: The Danish Rheumatism Association, Nordforsk, Finska Läkaresällskapet.
Abstract (Originalsprache)
OBJECTIVES: The European Alliance of Associations for Rheumatology (EULAR) recently proposed a framework for 'difficult-to-manage' (D2M) and 'treatment-refractory' disease in psoriatic arthritis (PsA). We explored real-world prevalence and characteristics of patients fulfilling registry-based components inspired by EULAR's framework among patients with PsA initiating biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD). METHODS: Cohort study from 5 Nordic biologics registries with follow-up of patients initiating first b/tsDMARD 1999 to 2020. First (step 1a), 3 cohorts were defined: discontinuation of ≥2, ≥3, or ≥4 b/tsDMARDs, respectively. Additional components were added sequentially to each cohort: (1b) b/tsDMARD-discontinuation reason (inefficacy/side effects); (1c) discontinuation of ≥2 different mechanisms of action (with 1a+1b+1c providing nuanced understanding of switching patterns); (2) problematic signs/symptoms (patient global score ≥ 30 mm); (3) persistent disease activity (tender/swollen joint count ≥1, C-reactive protein [CRP] > 10 mg/L, or Disease Activity index in PSoriatic Arthritis 28-joint counts >14). Treatment-refractory disease required primary/secondary b/tsDMARD inefficacy (not side-effects/intolerability/contraindications), and objective inflammation (tender/swollen joint count ≥ 1, or CRP > 10 mg/L). RESULTS: Among 14,362 patients, discontinuation of ≥2/≥3/≥4 b/tsDMARDs occurred in 36%/18%/10%, respectively, during a median(IQR) follow-up of 6.3 years (2.4-10.7). Applying all components (1a-3), D2M prevalences were 2%/3%/3%, respectively. Corresponding treatment-refractory prevalences were 1.2%/1.2%/0.8%, respectively. Female sex, depression, and opioid use increased with the number of b/tsDMARD discontinuations. CONCLUSIONS: In routine care, multiple b/tsDMARD discontinuations were common. Two percent were D2M, and 1.2% were treatment-refractory, both characterised by a higher prevalence of women, depression, and opioid use. Although our retrospective design did not allow testing of the EULAR definitions, our findings highlight the complexity of D2M and treatment-refractory PsA and underline the need for prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases and the DANBIO Registry, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital - Rigshospitalet, Glost…
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Division of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland.
- Research Centre for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
- Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Förderung
- The Danish Rheumatism Association
- Nordforsk
- Finska Läkaresällskapet
- Vinnova
- Foundation for Research in Rheumatology
- Norges Forskningsråd
Zitieren
APA
Nielung, L. M., Giuseppe, D. D., Hetland, M. L., Askling, J., Nordström, D. C., Provan, S. A., Gudbjornsson, B., Palsson, O., Delcoigne, B., Dreyer, L. W., Michelsen, B., Wallman, J. K., & Glintborg, B. (2026). Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries. Annals of the Rheumatic Diseases, 85(11), 2164-2173. https://doi.org/10.1016/j.ard.2026.08.002
Vancouver
Nielung LM, Giuseppe DD, Hetland ML, Askling J, Nordström DC, Provan SA, et al. Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries. Annals of the Rheumatic Diseases. 2026;85(11):2164-2173. doi:10.1016/j.ard.2026.08.002
BibTeX
@article{Nielung2026,
author = {Nielung, Louise Majormoen and Giuseppe, Daniela Di and Hetland, Merete Lund and Askling, Johan and Nordström, Dan C and Provan, Sella Aarrestad and Gudbjornsson, Bjorn and Palsson, Olafur and Delcoigne, Bénédicte and Dreyer, Lene Wohlfahrt and Michelsen, Brigitte and Wallman, Johan Karlsson and Glintborg, Bente},
title = {Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {11},
pages = {2164--2173},
doi = {10.1016/j.ard.2026.08.002}
}
EUVIMED